Tickers

1. Composite Trajectory Verdict

For a commercial-stage biopharmaceutical company with multiple approved products and an expanding pipeline, the income statement (revenue growth and operating loss trajectory) and cash flow statement (operating cash generation and runway) carry the most weight, while the balance sheet reflects financing-driven liquidity changes.

Composite Trajectory: Mixed

The annual 2025 results show clear improvement: revenue grew 55% year-over-year to $521.3 million, the operating loss narrowed 75% to $22.1 million, and operating cash flow turned positive at $55.8 million (10-K 2025-12-31, Consolidated Statements of Operations and Cash Flows). However, the first half of 2026 shows sharp deterioration driven by acquisition-related charges: six-month net loss widened to $857.4 million from $20.5 million due to a $742.7 million acquired in-process R&D charge (primarily Bluejay), and operating cash flow swung to -$273.0 million from +$10.1 million (10-Q 2026-06-30, Consolidated Statements of Operations and Cash Flows). The balance sheet reflects this duality: annual equity increased to $314.7 million, but June 2026 equity turned negative (-$10.4 million) after the Bluejay Acquisition and convertible note issuance (10-K 2025-12-31 and 10-Q 2026-06-30, Consolidated Balance Sheets).

2. Red Flags

• Six-month net loss of $857.4 million vs $20.5 million year-over-year, driven by a $742.7 million acquired IPR&D charge ($726.3 million Bluejay + $16.4 million Incyte) (10-Q 2026-06-30, MD&A and Consolidated Statements of Operations)
• Quarterly net loss of $67.2 million vs $5.9 million year-over-year, including $16.4 million acquired IPR&D and $34.7 million accelerated stock compensation from Bluejay (10-Q 2026-06-30, MD&A)
• Operating cash flow swung to -$273.0 million for six months ended June 2026 from +$10.1 million in 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows)
• Accumulated deficit doubled to $1.525 billion at June 30, 2026 from $667.5 million at December 31, 2025 (10-Q 2026-06-30, Consolidated Balance Sheets)
• Convertible notes increased to $750.1 million at June 30, 2026 from $309.8 million at December 31, 2025 following $690 million 0% 2032 Notes issuance (10-Q 2026-06-30, Consolidated Balance Sheets and MD&A)
• Stockholders' equity turned negative (-$10.4 million) at June 30, 2026 from positive $314.7 million at December 31, 2025 (10-Q 2026-06-30, Consolidated Balance Sheets)
• Quarterly operating loss widened to $42.5 million from $5.0 million year-over-year despite 38% revenue growth (10-Q 2026-06-30, Consolidated Statements of Operations)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show strong improvement: 2025 revenue increased 55% to $521.3 million (Livmarli +69% to $360.0 million; Bile Acid Medicines +31% to $161.3 million), operating loss narrowed 75% to $22.1 million, and net loss narrowed 73% to $23.4 million (10-K 2025-12-31, Consolidated Statements of Operations). Quarterly results show sharp deterioration: Q2 2026 revenue grew 38% to $176.2 million, but net loss widened to $67.2 million from $5.9 million due to $16.4 million acquired IPR&D (Incyte) and $34.7 million accelerated stock compensation (Bluejay) (10-Q 2026-06-30, MD&A and Consolidated Statements of Operations). Six-month net loss of $857.4 million reflects the $742.7 million Bluejay/Incyte IPR&D charge (10-Q 2026-06-30, MD&A). The annual trend reflects underlying commercial momentum; the quarterly trend reflects one-time acquisition accounting.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow improved significantly to $55.8 million in 2025 from $10.3 million in 2024, driven by higher revenue and working capital changes (10-K 2025-12-31, Consolidated Statements of Cash Flows). Six-month operating cash flow deteriorated to -$273.0 million in 2026 from +$10.1 million in 2025, reflecting the net loss impact of acquisition charges and working capital shifts including increased holdback liabilities and clinical accruals (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing cash flows surged to $481.5 million in six months 2026 (vs $15.0 million in 2025) from the 2032 Notes issuance, private placement, and 2029 Notes repurchase (10-Q 2026-06-30, MD&A and Cash Flows). Unrestricted cash and investments increased to $561.3 million at June 30, 2026 from $391.4 million at December 31, 2025 (10-Q 2026-06-30, MD&A).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Annual comparison (Dec 2025 vs Dec 2024): cash and investments rose to $391.4 million from $292.8 million; convertible notes stable at ~$310 million; total stockholders' equity increased to $314.7 million from $225.6 million (10-K 2025-12-31, Consolidated Balance Sheets). Quarterly comparison (June 2026 vs Dec 2025): cash and investments rose to $561.3 million from $391.4 million; convertible notes jumped to $750.1 million from $309.8 million; total liabilities doubled to $1.055 billion from $528.1 million; accumulated deficit increased to $1.525 billion from $667.5 million; stockholders' equity turned negative at -$10.4 million from +$314.7 million (10-Q 2026-06-30, Consolidated Balance Sheets). The balance sheet reflects financing-driven liquidity enhancement offset by acquisition-related liability and deficit expansion.

6. Data Gaps

• Standalone Q1 2026 quarterly results (only six-month YTD and Q2 2026 provided)
• Q3 2025 and Q4 2025 quarterly results (only full-year 2025 provided)
• Full-year 2026 results (not yet filed)
• Detailed breakdown of variable consideration estimates for Takeda/distributor revenue
• Segment-level profitability beyond single-segment disclosure
• Post-June 2026 cash burn rate excluding one-time acquisition charges